Benzinga - by Avi Kapoor, Benzinga Staff Writer.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy .
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
Amgen Inc. (NASDAQ: AMGN)
- Dividend Yield: 3.29%
- Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price target from $281 to $278 on Feb. 7, 2024. This analyst has an accuracy rate of 67%.
- RBC Capital analyst Gregory Renza maintained an Outperform rating and raised the price target from $303 to $329 on Feb. 7, 2024. This analyst has an accuracy rate of 72%.
- Recent News: On Feb. 26, Amgen announced the opening of its manufacturing site in Central Ohio, the newest in its global operations network and the most advanced facility to date.
- Dividend Yield: 3.31%
- Oppenheimer analyst Steven Lichtman maintained a Perform rating and raised the price target from $89 to $92 on Feb. 21, 2024. This analyst has an accuracy rate of 73%.
- Truist Securities analyst Richard Newitter maintained a Hold rating and boosted the price target from $87 to $90 on Feb. 21, 2024. This analyst has an accuracy rate of 73%.
- Recent News: On Feb. 29, Medtronic filed ITC action against Axonics to stop unauthorized use of Medtronic innovations.
- Dividend Yield: 3.52%
- Truist Securities analyst Robyn Karnauskas maintained a Buy rating and raised the price target from $180 to $195 on Feb. 6, 2024. This analyst has an accuracy rate of 66%.
- HSBC analyst Rajesh Kumar downgraded the stock from Buy to Hold and slashed the price target from $167 to $156 on Dec. 18, 2023. This analyst has an accuracy rate of 68%.
- Recent News: On Feb. 28, AbbVie and OSE Immunotherapeutics entered into strategic partnership to develop a novel monoclonal antibody for the treatment of chronic inflammation.
Read More: Dell, SoundHound AI And 3 Stocks To Watch Heading Into Friday
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.